Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05200871 · ClinicalTrials.gov registry record
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
A clinical trial of Focal Segmental Glomerulosclerosis and Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.
- Completed
- Registry status
- 487
- Enrollment target
- 6
- Study locations
NCT05200871: Completed study of Focal Segmental Glomerulosclerosis and Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.
NCT05200871 is a study of Focal Segmental Glomerulosclerosis and Immunoglobulin A Nephropathy that has completed, run by Travere Therapeutics. The registered enrollment target is 487 participants, above the 211-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (131% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05200871, a study of Focal Segmental Glomerulosclerosis and Immunoglobulin A Nephropathy, has completed, sponsored by Travere Therapeutics.
- COMPLETED
- Registry status
- 487 participants
- Enrollment target
- 6
- Study locations
Study Summary
The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States \[US\], United Kingdom \[UK\], France, Germany, Italy and Spain).
Primary Outcome
Adult patients (self-reported) - age, sex, education level, household income, marital status, current work status, race/ethnicity (for patients in the US and in the UK), health insurance (for patients in the US), approximate travel time to receive FSGS/IgAN medical care. Child/adolescent patients (reported by parent/care-partner) - age, sex, current school status, race/ethnicity (for patients in the US and in the UK), approximate travel time to receive FSGS/IgAN medical care. Care-partners of
Conditions Studied
Study Locations (6)
Other
- Travere Investigational Site - Villingen-Schwenningen
- Travere Investigational Site - Madrid
California
- Travere Investigational Site - San Francisco
New Jersey
- Travere Investigational Site - Belmar
North Carolina
- Travere Investigational Site - Chapel Hill
Pennsylvania
- Travere Investigational Site - King of Prussia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2022-02-05 |
| Est. Completion | 2023-10-31 |
What the finished NCT05200871 record still lists
NCT05200871 is an observational study that tracks outcomes without assigning an intervention. The registered 487 participants enrollment target is mid-sized for trials with a published cap, above the 211-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (131% higher).
The record links to 2 conditions, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT05200871 lists 6 locations in 5 states (Other, California, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05200871 about?
NCT05200871 is a clinical study titled "Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)". The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States \[US\], United Kingdom \[UK\], France, Germany, Italy and Spain).
What is the current status of trial NCT05200871?
This trial is currently completed. The enrollment target is 487 participants. The study started on 2022-02-05. Estimated completion is 2023-10-31.
What conditions does trial NCT05200871 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy.
Who is sponsoring clinical trial NCT05200871?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05200871 being conducted?
This trial has 6 study locations across California, New Jersey, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05200871's enrollment target sits among peer trials
487 2nd of 19 the highest of 19 other Focal Segmental Glomerulosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Focal Segmental Glomerulosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
-
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
RECRUITING · Phase 2
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
RECRUITING · Phase 3
-
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
RECRUITING · NA
-
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- NCT06952530 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- NCT05154669 · 488 participants · Phase 3
Integrating Financial Coaching and Smoking Cessation Coaching
- NCT06532877 · 488 participants · NA
Telephone Support in Advanced Gastrointestinal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI